BusinessNew Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals’ PS-Targeting Antibodies in a Preclinical Melanoma ModelBy Nasdaq OMXNov 14, 2016, 1:05 PM UTC
BusinessFluidigm Introduces High-Parameter Maxpar Mass Cytometry Panels for Immuno-Oncology ResearchBy Nasdaq OMXNov 10, 2016, 1:30 PM UTC
BusinessGalectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin DiseasesBy Nasdaq OMXNov 10, 2016, 1:00 PM UTC
BusinessFluidigm and GenomOncology Partner to Provide Automated Oncology NGS Library Preparation With Molecular Interpretation and ReportingBy Nasdaq OMXNov 9, 2016, 1:00 PM UTC
BusinessGalectin Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business UpdateBy Nasdaq OMXNov 8, 2016, 1:00 PM UTC
BusinessKura Oncology Reports Third Quarter 2016 Financial ResultsBy Nasdaq OMXNov 7, 2016, 9:05 PM UTC
BusinessKura Oncology Presents Update on Pipeline Programs Targeting RAS-ERK Pathway at European Scientific Oncology ConferenceBy Nasdaq OMXNov 4, 2016, 11:30 AM UTC
BusinessKura Oncology to Participate in Two Upcoming Investor ConferencesBy Nasdaq OMXNov 1, 2016, 8:05 PM UTC
